Immunogenicity Clinical Trial
Official title:
Protectivity and Safety Following Recombinant Hepatitis B Vaccine With Different Source of Hepatitis B Bulk Compared to Hepatitis B (Bio Farma) Vaccine in Indonesian Population
Verified date | September 2022 |
Source | PT Bio Farma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population
Status | Completed |
Enrollment | 536 |
Est. completion date | February 28, 2020 |
Est. primary completion date | January 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 10 Years to 40 Years |
Eligibility | Inclusion Criteria: 1. Healthy individu as determined by clinical judgment, including a medical history and physical exam which confirms the absence of a current or past disease state considered significant by the investigator. 2. Subjects/parents/guardian(s) have been informed properly regarding the study and signed the informed consent form/ informed assent form. 3. Subject/parents/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial. Exclusion Criteria: 1. Subject concomitantly enrolled or scheduled to be enrolled in another trial. 2. Subjects with known history of Hepatitis B contained vaccination in the last 10 years 3. Evolving severe illness and/or chronic disease and fever (axillary temperature more than37.5oC) within the 48 hours preceding enrollment. 4. Known history of allergy to any component of the vaccines (based on anamnesis) 5. HBsAg positive 6. Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy). 7. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. 8. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or corticosteroid therapy and other immunosuppresant. 9. Pregnancy & Lactation (Adult) 10. Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization. |
Country | Name | City | State |
---|---|---|---|
Indonesia | RSND | Semarang | Central Java |
Lead Sponsor | Collaborator |
---|---|
PT Bio Farma |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of subjects with increasing antibody titer >= 4 times | Percentage of subjects with increasing antibody titer >= 4 times: in all subjects; comparison between investigational product and control and between each lot number of Recombinant Hepatitis B | 28 days after the last dose immunization | |
Secondary | Geometric Mean Titer (GMT) | GMT in all subjects; comparison of GMT between investigational products and control and comparison of GMT between each lot number of Recombinant Hepatitis B | 28 days after the last dose immunization | |
Secondary | Percentage of subjects with transition of seronegative to seropositive | Percentage of subjects with transition of seronegative to seropositive: in all subjects; Subjets which get investigational products and control and each lot number of Recombinant Hepatitis B | 28 days after the last dose immunization | |
Secondary | Percentage of subjects with at least one immediate reaction | Immediate reaction (local reaction or systemic event) | 30 minutes after each vaccination | |
Secondary | Percentage of subjects with at least one of these adverse events | At least one of these adverse events, expected or not | within 72 hours, between 72 hours to 28 days after vaccination | |
Secondary | Serious adverse event after vaccination | Serious adverse event occurring from inclusion until 28 days after vaccination. | 28 days after the last dose immunization | |
Secondary | Comparison adverse events between Investigational Products (Hepatitis B) and Control | Adverse events occuring until 28 days after vaccination | 28 days after each dose | |
Secondary | Comparison of adverse events between each lot number of Recombinant Hepatitis B vaccine | Adverse events occuring until 28 days after vaccination | 28 days after each dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05383560 -
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
|
Phase 2 | |
Recruiting |
NCT01763268 -
Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
|
Phase 2/Phase 3 | |
Recruiting |
NCT05054621 -
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
|
Phase 2 | |
Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 | |
Completed |
NCT04071379 -
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B
|
Phase 3 | |
Completed |
NCT01697007 -
A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique
|
Phase 2 | |
Completed |
NCT03680417 -
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
|
Phase 4 | |
Completed |
NCT03722615 -
Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
|
||
Completed |
NCT01369927 -
Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
|
Phase 1 | |
Completed |
NCT04051268 -
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
|
Phase 3 | |
Recruiting |
NCT05115617 -
Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study
|
||
Not yet recruiting |
NCT05911087 -
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2
|
Phase 2/Phase 3 | |
Completed |
NCT01092195 -
Gardasil Vaccination in Post Stem Cell Transplant Patients
|
Phase 1 | |
Completed |
NCT01399853 -
A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants
|
Phase 2 | |
Completed |
NCT03460405 -
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants
|
Phase 2 | |
Completed |
NCT03681860 -
EMaBS TB Vaccine Study
|
Phase 1/Phase 2 | |
Completed |
NCT04754698 -
COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS
|
Phase 4 | |
Completed |
NCT04015232 -
Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
|
Phase 1 | |
Recruiting |
NCT05150834 -
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
|